|
1
|
Man S, Gao W, Wei C and Liu C: Anticancer
drugs from traditional toxic Chinese medicines. Phytother Res.
26:1449–1465. 2012.PubMed/NCBI
|
|
2
|
Soignet SL, Maslak P, Wang ZG, et al:
Complete remission after treatment of acute promyelocytic leukemia
with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu J, Chew EH and Holmgren A: Targeting
thioredoxin reductase is a basis for cancer therapy by arsenic
trioxide. Proc Natl Acad Sci USA. 104:12288–12293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu J, Liu YF, Wu CF, et al: Long-term
efficacy and safety of all-trans retinoic acid/arsenic
trioxide-based therapy in newly diagnosed acute promyelocytic
leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim J, Lee JJ, Kim J, Gardner D and Beachy
PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary
accumulation and reducing stability of the Gli2 transcriptional
effector. Proc Natl Acad Sci USA. 107:13432–13437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic
trioxide controls the fate of the PML-RARalpha oncoprotein by
directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mahieux R, Pise-Masison C, Gessain A, et
al: Arsenic trioxide induces apoptosis in human T-cell leukemia
virus type 1- and type 2-infected cells by a caspase-3-dependent
mechanism involving Bcl-2 cleavage. Blood. 98:3762–3769. 2001.
View Article : Google Scholar
|
|
8
|
Bae-Jump VL, Zhou C, Boggess JF and Gehrig
PA: Arsenic trioxide (As2O3) inhibits
expression of estrogen receptor-alpha through regulation of the
mitogen-activated protein kinase (MAPK) pathway in endometrial
cancer cells. Reprod Sci. 15:1011–1017. 2008.
|
|
9
|
Kang YH and Lee SJ: The role of p38 MAPK
and JNK in Arsenic trioxide-induced mitochondrial cell death in
human cervical cancer cells. J Cell Physiol. 217:23–33. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahn RW, Chen F, Chen H, et al: A novel
nanoparticulate formulation of arsenic trioxide with enhanced
therapeutic efficacy in a murine model of breast cancer. Clin
Cancer Res. 16:3607–3617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raju GP: Arsenic: a potentially useful
poison for Hedgehog-driven cancers. J Clin Invest. 121:14–16. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu XM, Liu F and Ma R: Application and
assessment of Chinese arsenic drugs in treating malignant
hematopathy in China. Chin J Integr Med. 16:368–377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang Y, Wang XB, Sun SJ, et al: Compound
huangdai tablet as induction therapy for 193 patients with acute
promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 30:440–442.
2009.(In Chinese).
|
|
14
|
Li JE, Wu WL, Wang ZY and Sun GL:
Apoptotic effect of As2S2 on K562 cells and
its mechanism. Acta Pharmacol Sin. 23:991–996. 2002.
|
|
15
|
Mao JH, Sun XY, Liu JX, et al:
As4S4 targets RING-type E3 ligase c-CBL to
induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc
Natl Acad Sci USA. 107:21683–21688. 2010.PubMed/NCBI
|
|
16
|
Bairey O, Vanichkin A and Shpilberg O:
Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia
cells. Int J Lab Hematol. 32(1 Pt 1): e77–e85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Redondo-Muñoz J, Escobar-Díaz E, Hernández
Del Cerro M, et al: Induction of B-chronic lymphocytic leukemia
cell apoptosis by arsenic trioxide involves suppression of the
phosphoinositide 3-kinase/Akt survival pathway via
c-jun-NH2 terminal kinase activation and PTEN
upregulation. Clin Cancer Res. 16:4382–4391. 2010.PubMed/NCBI
|
|
18
|
Yin T, Wu YL, Sun HP, et al: Combined
effects of As4S4 and imatinib on chronic
myeloid leukemia cells and BCR-ABL oncoprotein. Blood.
104:4219–4225. 2004.
|
|
19
|
Zhao QH, Zhang Y, Liu Y, et al: Anticancer
effect of realgar nanoparticles on mouse melanoma skin cancer in
vivo via transdermal drug delivery. Med Oncol. 27:203–212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
An YL, Nie F, Wang ZY and Zhang DS:
Preparation and characterization of realgar nanoparticles and their
inhibitory effect on rat glioma cells. Int J Nanomedicine.
6:3187–3194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng YX, Liu R, Wang Q, et al:
Realgar-induced apoptosis of cervical cancer cell line Siha via
cytochrome c release and caspase-3 and caspase-9 activation.
Chin J Integr Med. 18:359–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ye HQ, Gan L, Yang XL and Xu HB:
Membrane-associated cytotoxicity induced by realgar in
promyelocytic leukemia HL-60 cells. J Ethnopharmacol. 103:366–371.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang XB, Gao HY, Hou BL, Huang J, Xi RG
and Wu LJ: Nanoparticle realgar powders induce apoptosis in U937
cells through caspase MAPK and mitochondrial pathways. Arch Pharm
Res. 30:653–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xi RG, Huang J, Li D, Wang XB and Wu LJ:
Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced
apoptosis in U937 cells. Acta Pharmacol Sin. 29:355–363. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klein U and Dalla-Favera R: New insights
into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer
Biol. 20:377–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Damle RN, Calissano C and Chiorazzi N:
Chronic lymphocytic leukaemia: a disease of activated monoclonal B
cells. Best Pract Res Clin Haematol. 23:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stacchini A, Aragno M, Vallario A, et al:
MEC1 and MEC2: two new cell lines derived from B-chronic
lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res.
23:127–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buggins AG and Pepper CJ: The role of
Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res.
34:837–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
